

Roberto RodrÃ-guez Ibeas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/767969/publications.pdf>

Version: 2024-02-01

32
papers

319
citations

933447

10
h-index

888059

17
g-index

34
all docs

34
docs citations

34
times ranked

416
citing authors

#	ARTICLE	IF	CITATIONS
1	Environmental Product Differentiation and Environmental Awareness. <i>Environmental and Resource Economics</i> , 2007, 36, 237-254.	3.2	62
2	Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. <i>Health Economics, Policy and Law</i> , 2011, 6, 391-403.	1.8	39
3	The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. <i>Pharmacoeconomics</i> , 2019, 37, 1469-1483.	3.3	36
4	Transferability indices for health economic evaluations: methods and applications. <i>Health Economics (United Kingdom)</i> , 2009, 18, 629-643.	1.7	30
5	Some economics on personalized and predictive medicine. <i>European Journal of Health Economics</i> , 2015, 16, 985-994.	2.8	18
6	Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?. <i>Pharmacoeconomics</i> , 2018, 36, 733-743.	3.3	18
7	Genetic testing in the European Union: does economic evaluation matter?. <i>European Journal of Health Economics</i> , 2012, 13, 651-661.	2.8	13
8	Methodological reviews of economic evaluations in health care: what do they target?. <i>European Journal of Health Economics</i> , 2014, 15, 829-840.	2.8	12
9	Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model. <i>Health Economics Review</i> , 2021, 11, 29.	2.0	12
10	Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists. <i>Health Economics Review</i> , 2019, 9, 25.	2.0	9
11	Alcohol consumption in the EU: health economics and policy issues under a permanent debate. <i>European Journal of Health Economics</i> , 2008, 9, 1-6.	2.8	6
12	Efficiency of Diagnostic Testing for Helicobacter pylori Infections – A Systematic Review. <i>Antibiotics</i> , 2021, 10, 55.	3.7	6
13	Channeling health economics research initiatives to improve decision-making processes in the EU. <i>European Journal of Health Economics</i> , 2013, 14, 847-852.	2.8	5
14	Healthy vs. unhealthy food: a strategic choice for firms and consumers. <i>Health Economics Review</i> , 2011, 1, 4.	2.0	4
15	Should the patent system for pharmaceuticals be replaced? A theoretical approach. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 617-626.	1.4	4
16	Is personalized medicine a panacea for health management? Some thoughts on its desirability. <i>European Journal of Health Economics</i> , 2015, 16, 455-457.	2.8	4
17	EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?. <i>European Journal of Health Economics</i> , 2018, 19, 905-907.	2.8	4
18	Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad. <i>European Journal of Health Economics</i> , 2011, 12, 393-395.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Innovation, loyalty and generic competition in pharmaceutical markets. SERIEs, 2011, 2, 75-95.	1.4	3
20	Improving health care systems by building "more Europe"™. European Journal of Health Economics, 2016, 17, 787-789.	2.8	3
21	Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach. Health Economics Review, 2019, 9, 28.	2.0	3
22	Honesty in Environmental Regulation. Journal of Regulatory Economics, 2003, 24, 35-48.	1.4	2
23	Environmental regulatory enforcement with "green" consumers. Spanish Economic Review, 2006, 8, 271-283.	1.0	2
24	Comentario. Coste-efectividad e impacto presupuestario en la toma de decisiones de introducción de nuevas tecnologías: comentarios al artículo de Pinto et al. Gaceta Sanitaria, 2008, 22, 593-595.	1.5	2
25	Coping with uncertainty on health decisions: assessing new solutions. European Journal of Health Economics, 2012, 13, 375-378.	2.8	2
26	Implementing personalized medicine with asymmetric information on prevalence rates. Health Economics Review, 2016, 6, 35.	2.0	2
27	Endogenous versus exogenous generic reference pricing for pharmaceuticals. International Journal of Health Economics and Management, 2017, 17, 413-432.	1.1	2
28	Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations. Antibiotics, 2022, 11, 27.	3.7	1
29	A hybrid equilibrium in segmented markets: the three-firm case. Journal of Economics/ Zeitschrift Fur Nationalökonomie, 2000, 72, 81-97.	0.7	0
30	PHP150 Pharmaceutical Pricing Under Uncertainty: Risk-Sharing Contracts. Value in Health, 2011, 14, A360.	0.3	0
31	PHP153 Some Shortages and Alternatives to the Patent System for Pharmaceuticals. Value in Health, 2011, 14, A361.	0.3	0
32	Efficient health research and improving Europeans'™ health. European Journal of Health Economics, 2015, 16, 913-915.	2.8	0